Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 22, 2026 18:11 ET | Source: The Rosen Law Firm PA

IBRX DEADLINE NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages ImmunityBio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important May 26 Deadline in Securities Class Action First Filed by the Firm - IBRX

NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of ImmunityBio, Inc. (NASDAQ: IBRX) between January 19, 2026 and...
May 22, 2026 16:05 ET | Source: Bragar Eagel & Squire

IMMUNITYBIO CLASS ACTION DEADLINE TUESDAY MAY 26th: Bragar Eagel & Squire, P.C. Urges Immunity Bio, Inc. Stockholders with Significant Losses to Contact the Firm Regarding Their Rights Before May 26th

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In ImmunityBio (IBRX) To Contact Him Directly To Discuss Their Options If you purchased or...
May 22, 2026 12:48 ET | Source: Hagens Berman Sobol Shapiro LLP

IBRX 4-DAY DEADLINE ALERT: ImmunityBio (IBRX) Investors Face Losses Amid FDA Warning Regarding Unsupported Cancer Treatment Claims – Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.
May 22, 2026 06:05 ET | Source: Robbins Geller Rudman & Dowd LLP

TUESDAY INVESTOR DEADLINE: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

The case alleges ImmunityBio materially overstated Anktiva’s capabilities.
May 21, 2026 13:16 ET | Source: SkyMedia, LLC

ImmunityBio Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against ImmunityBio, Inc. - IBRX

NEW ORLEANS, May 21, 2026 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until May 26, 2026 to file lead plaintiff applications in a...
May 21, 2026 09:50 ET | Source: Schall Law

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm

IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm
May 20, 2026 09:03 ET | Source: Bernstein Liebhard LLP

IMMUNITYBIO, INC. INVESTORS WITH LOSSES HAVE UNTIL MAY 26, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline

ImmunityBio Shareholders Between January 19, 2026 and March 24, 2026 - Contact Bernstein Liebhard For More Information Regarding Shareholder Lawsuit
May 19, 2026 22:11 ET | Source: Kahn Swick & Foti, LLC

ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

ImmunityBio (IBRX) Investors Have Opportunity to Lead ImmunityBio, Inc Securities Fraud Lawsuit
May 19, 2026 09:14 ET | Source: Berger Montague

CLASS ACTION REMINDER: Berger Montague Advises ImmunityBio, Inc. (NASDAQ: IBRX) Investors to Inquire About a Securities Fraud Lawsuit by May 26, 2026

PHILADELPHIA, May 19, 2026 (GLOBE NEWSWIRE) -- National plaintiffs’ law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) (“ImmunityBio” or the...
May 19, 2026 09:06 ET | Source: Hagens Berman Sobol Shapiro LLP

ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman

Investors who lost money in IBRX after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.